193 related articles for article (PubMed ID: 25965177)
1. A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.
Jeay S; Gaulis S; Ferretti S; Bitter H; Ito M; Valat T; Murakami M; Ruetz S; Guthy DA; Rynn C; Jensen MR; Wiesmann M; Kallen J; Furet P; Gessier F; Holzer P; Masuya K; Würthner J; Halilovic E; Hofmann F; Sellers WR; Graus Porta D
Elife; 2015 May; 4():. PubMed ID: 25965177
[TBL] [Abstract][Full Text] [Related]
2. The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1.
Reuther C; Heinzle V; Nölting S; Herterich S; Hahner S; Halilovic E; Jeay S; Wuerthner JU; Aristizabal Prada ET; Spöttl G; Maurer J; Auernhammer CJ
Neuroendocrinology; 2018; 106(1):1-19. PubMed ID: 27871087
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.
Weisberg E; Halilovic E; Cooke VG; Nonami A; Ren T; Sanda T; Simkin I; Yuan J; Antonakos B; Barys L; Ito M; Stone R; Galinsky I; Cowens K; Nelson E; Sattler M; Jeay S; Wuerthner JU; McDonough SM; Wiesmann M; Griffin JD
Mol Cancer Ther; 2015 Oct; 14(10):2249-59. PubMed ID: 26206331
[TBL] [Abstract][Full Text] [Related]
4. A signature for success.
Espinosa JM; Sullivan KD
Elife; 2015 Jun; 4():. PubMed ID: 26079875
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
Holzer P; Masuya K; Furet P; Kallen J; Valat-Stachyra T; Ferretti S; Berghausen J; Bouisset-Leonard M; Buschmann N; Pissot-Soldermann C; Rynn C; Ruetz S; Stutz S; Chène P; Jeay S; Gessier F
J Med Chem; 2015 Aug; 58(16):6348-58. PubMed ID: 26181851
[TBL] [Abstract][Full Text] [Related]
6. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.
Maser T; Zagorski J; Kelly S; Ostrander A; Goodyke A; Nagulapally A; Bond J; Park Y; Saulnier Sholler G
Cancer Med; 2020 Nov; 9(21):8144-8158. PubMed ID: 33034426
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument.
Furet P; Masuya K; Kallen J; Stachyra-Valat T; Ruetz S; Guagnano V; Holzer P; Mah R; Stutz S; Vaupel A; Chène P; Jeay S; Schlapbach A
Bioorg Med Chem Lett; 2016 Oct; 26(19):4837-4841. PubMed ID: 27542305
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies.
Bauer S; Demetri GD; Halilovic E; Dummer R; Meille C; Tan DSW; Guerreiro N; Jullion A; Ferretti S; Jeay S; Van Bree L; Hourcade-Potelleret F; Wuerthner JU; Fabre C; Cassier PA
Br J Cancer; 2021 Aug; 125(5):687-698. PubMed ID: 34140638
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.
Carita G; Frisch-Dit-Leitz E; Dahmani A; Raymondie C; Cassoux N; Piperno-Neumann S; Némati F; Laurent C; De Koning L; Halilovic E; Jeay S; Wylie A; Emery C; Roman-Roman S; Schoumacher M; Decaudin D
Oncotarget; 2016 Jun; 7(23):33542-56. PubMed ID: 27507190
[TBL] [Abstract][Full Text] [Related]
10. NVP-CGM097, an HDM2 Inhibitor, Antagonizes ATP-Binding Cassette Subfamily B Member 1-Mediated Drug Resistance.
Zhang M; Chen XY; Dong XD; Wang JQ; Feng W; Teng QX; Cui Q; Li J; Li XQ; Chen ZS
Front Oncol; 2020; 10():1219. PubMed ID: 32793491
[TBL] [Abstract][Full Text] [Related]
11. Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors.
Sonkin D
Elife; 2015 Oct; 4():. PubMed ID: 26491944
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT
Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686
[TBL] [Abstract][Full Text] [Related]
13. Hodgkin's lymphoma cells express alternatively spliced forms of HDM2 with multiple effects on cell cycle control.
Sánchez-Aguilera A; García JF; Sánchez-Beato M; Piris MA
Oncogene; 2006 Apr; 25(18):2565-74. PubMed ID: 16331255
[TBL] [Abstract][Full Text] [Related]
14. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
Lau LM; Nugent JK; Zhao X; Irwin MS
Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
[TBL] [Abstract][Full Text] [Related]
15. Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.
Jeay S; Gaulis S; Ferretti S; Bitter H; Ito M; Valat T; Murakami M; Ruetz S; Guthy DA; Rynn C; Jensen MR; Wiesmann M; Kallen J; Furet P; Gessier F; Holzer P; Masuya K; Würthner J; Halilovic E; Hofmann F; Sellers WR; Graus Porta D
Elife; 2016 Nov; 5():. PubMed ID: 27852439
[No Abstract] [Full Text] [Related]
16. Discovery of Potent and Selective p53-MDM2 Protein-Protein Interaction Inhibitors as Anticancer Drugs.
Holzer P
Chimia (Aarau); 2017 Oct; 71(10):716-721. PubMed ID: 29070416
[TBL] [Abstract][Full Text] [Related]
17. Network perspectives on HDM2 inhibitor chemotherapy combinations.
Azmi AS; Beck FW; Sarkar FH; Mohammad RM
Curr Pharm Des; 2011; 17(6):640-52. PubMed ID: 21391913
[TBL] [Abstract][Full Text] [Related]
18. Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2.
LaRusch GA; Jackson MW; Dunbar JD; Warren RS; Donner DB; Mayo LD
Cancer Res; 2007 Jan; 67(2):450-4. PubMed ID: 17234751
[TBL] [Abstract][Full Text] [Related]
19. Hdm2 and nitric oxide radicals contribute to the p53-dependent radioadaptive response.
Takahashi A; Matsumoto H; Ohnishi T
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):550-8. PubMed ID: 18410999
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
